Evaluating the Phoenix definition of biochemical failure after 125I prostate brachytherapy: Can PSA kinetics distinguish PSA failures from PSA bounces?

International Journal of Radiation Oncology Biology Physics

Volumn 78, Issue 2, 2010, Pages 415-421

  Thompson, Anna ^a   Keyes, Mira ^a   Pickles, Tom ^a   Palma, David ^a   Moravan, Veronika ^a   Spadinger, Ingrid ^a   Lapointe, Vincent ^a   Morris, W James ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Prostate brachytherapy; Prostate cancer; Prostate specific antigen bounce; Prostate specific antigen failure; Prostate specific antigen kinetics

Indexed keywords

BIOCHEMICAL FAILURE; CHI-SQUARE TESTS; POTENTIAL MINIMA; PROSTATE BRACHYTHERAPY; PROSTATE CANCERS; PROSTATE SPECIFIC ANTIGEN; PSA DOUBLING TIME; PSA FAILURE;

DISEASES; DOSIMETRY; ONCOLOGY; PATIENT MONITORING; RADIOTHERAPY; REGRESSION ANALYSIS;

ANTIGENS;

ANTIANDROGEN; GONADORELIN AGONIST; IODINE 125; PROSTATE SPECIFIC ANTIGEN; RADIOACTIVE IODINE; TESTOSTERONE;

ADJUVANT THERAPY; ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RISK; CHI SQUARE TEST; CONTROLLED STUDY; DOSIMETRY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT FAILURE; TREATMENT OUTCOME; AGE; CHI SQUARE DISTRIBUTION; EVALUATION STUDY; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROSPECTIVE STUDY; PROSTATIC NEOPLASMS; REFERENCE VALUE; TIME; TUMOR RECURRENCE; TUMOR VOLUME; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BRACHYTHERAPY; CHI-SQUARE DISTRIBUTION; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REFERENCE VALUES; TESTOSTERONE; TIME FACTORS; TREATMENT FAILURE; TUMOR BURDEN;

EID: 77954100198     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.07.1724     Document Type: Article

References (30)

1. J.A. Cesaretti, N.N. Stone, and V.M. Skouteris Brachytherapy for the treatment of prostate cancer Cancer J 13 2007 302 312
2. L. Potters, C. Morgenstern, and E. Calugaru 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer J Urol 173 2005 1562 1566
3. P.D. Grimm, J.C. Blasko, and J.E. Sylvester 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy Int J Radiat Oncol Biol Phys 51 2001 31 40
4. C. Patel, M.A. Elshaikh, and K. Angermeier PSA bounce predicts early success in patients with permanent iodine-125 prostate implant Urology 63 2004 110 113
5. W. Cavanagh, J.C. Blasko, and P.D. Grimm Transient elevation of serum prostate-specific antigen following (125)I/(103)Pd brachytherapy for localized prostate cancer Semin Urol Oncol 18 2000 160 165
6. R.G. Stock, N.N. Stone, and J.A. Cesaretti Prostate-specific antigen bounce after prostate seed implantation for localized prostate cancer: Descriptions and implications Int J Radiat Oncol Biol Phys 56 2003 448 453
7. J. Crook, S. Malone, and G. Perry Postradiotherapy prostate biopsies: What do they really mean? Results for 498 patients Int J Radiat Oncol Biol Phys 48 2000 355 367
8. T. Pickles British Columbia Cancer Agency Prostate Cohort Outcomes Initiative. Prostate-specific antigen (PSA) bounce and other fluctuations: Which biochemical relapse definition is least prone to PSA false calls? An analysis of 2030 men treated for prostate cancer with external beam or brachytherapy with or without adjuvant androgen deprivation therapy Int J Radiat Oncol Biol Phys 64 2006 1355 1359
9. K.E. Wallner, J. Blasko, and M.J. Dattoli Prostate brachytherapy made complicated. Chapter 14. Evaluating cancer status 1997 Chapter: Smart Medicine Press p. 14.0-14.15. Smart Medicine, Seattle WA.
10. L. Potters, C. Cha, and G. Oshinsky Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy Cancer J Sci Am 5 1999 301 306
11. F.A. Critz, W.H. Williams, and A.K. Levinson Prostate specific antigen bounce after simultaneous irradiation for prostate cancer: The relationship to patient age J Urol 170 2003 1864 1867
12. J. Crook, C. Gillan, and I. Yeung PSA kinetics and PSA bounce following permanent seed prostate brachytherapy Int J Radiat Oncol Biol Phys 69 2007 426 433
13. C. Bostancic, G.S. Merrick, and W.M. Butler Isotope and patient age predict for PSA spikes after permanent prostate brachytherapy Int J Radiat Oncol Biol Phys 68 2007 1431 1437
14. P. Das, M.H. Chen, and K. Valentine Using the magnitude of PSA bounce after MRI-guided prostate brachytherapy to distinguish recurrence, benign precipitating factors, and idiopathic bounce Int J Radiat Oncol Biol Phys 54 2002 698 702
15. J.P. Ciezki, C.A. Reddy, and J. Garcia PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time Int J Radiat Oncol Biol Phys 64 2006 512 517
16. Caloglu M, Ciezki J. Prostate-specific antigen bounce after prostate brachytherapy: Review of a confusing phenomenon. Urology. In press
17. M. Roach 3rd, G. Hanks, and H. Thames Jr. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference Int J Radiat Oncol Biol Phys 65 2006 965 974
18. W.J. Morris, M. Keyes, and D. Palma Population-based study of biochemical and survival outcomes after permanent (125)I brachytherapy for low- and intermediate-risk prostate cancer Urology 73 2009 860 865 discussion 865-867
19. W.J. Morris, M. Keyes, and D. Palma Evaluation of dosimetric parameters and disease response after 125 iodine transperineal brachytherapy for low- and intermediate-risk prostate cancer Int J Radiat Oncol Biol Phys 73 2009 1432 1438
20. M. Keyes, D. Schellenberg, and V. Moravan Decline in urinary retention incidence in 805 patients after prostate brachytherapy: The effect of learning curve? Int J Radiat Oncol Biol Phys 64 2006 825 834
21. J. Sylvester, J.C. Blasko, and P. Grimm Interstitial implantation techniques in prostate cancer J Surg Oncol 66 1997 65 75
22. M. Keyes, S. Miller, and V. Moravan Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: Long-term outcome in 712 consecutive patients Int J Radiat Oncol Biol Phys 73 2009 1023 1032
23. Rectal Toxicity After I 125 Permanent Prostate Implants. Keyes M, Moravan V, Liu M, Jankovic B, Morris WJ. Radiotherapy & Oncology September 2005 (Vol. 76, Pages S5-S6).
24. A.G. Macdonald, M. Keyes, and A. Kruk Predictive factors for erectile dysfunction in men with prostate cancer after brachytherapy: Is dose to the penile bulb important? Int J Radiat Oncol Biol Phys 63 2005 155 163
25. D.M. Mitchell, R. Swindell, and T. Elliott Analysis of prostate-specific antigen bounce after I(125) permanent seed implant for localised prostate cancer Radiother Oncol 88 2008 102 107
26. M.J. Zelefsky, and M.J. Zelefsky PSA bounce versus biochemical failure following prostate brachytherapy Nat Clin Pract Urol 3 2006 578 579
27. M. Morita, J.L. Lederer, and T. Fukagai PSA bounce phenomenon after transperineal interstitial permanent prostate brachytherapy for localized prostate cancer Nippon Hinyokika Gakkai Zasshi 95 2004 609 615 (Pubitemid 38478292)
28. Quadrant dosimetry as a predictor of biochemical relapse in 125I prostate brachytherapy Ingrid Spadinger, James Morris W, Mira Keyes, Mitchell Liu, Nick Chng, Rahim Vellani, Ryan Woods Brachytherapy April 2009 (Vol. 8, Issue 2, Page 126).
29. Review of permanent interstitial 125I prostate brachytherapy patients treated with biochemical failure and a minimum of 4 years follow-up Anna C. Thompson, Tom Pickles, Mira Keyes, Ingrid Spadinger, William J. Morris Brachytherapy April 2008 (Vol. 7, Issue 2, Page 116).
30. G.S. Merrick, W.M. Butler, and K.E. Wallner Prostate-specific antigen spikes after permanent prostate brachytherapy Int J Radiat Oncol Biol Phys 54 2002 450 456